- Home
- FMC vs GH Comparison
FMC vs GH Comparison
Compare FMC & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMC
- GH
- Stock Information
- Founded
- FMC 1910
- GH 2011
- Country
- FMC United States
- GH United States
- Employees
- FMC N/A
- GH N/A
- Industry
- FMC Major Chemicals
- GH Medical Specialities
- Sector
- FMC Industrials
- GH Health Care
- Exchange
- FMC Nasdaq
- GH Nasdaq
- Market Cap
- FMC 4.6B
- GH 4.9B
- IPO Year
- FMC N/A
- GH 2018
- Fundamental
- Price
- FMC $30.82
- GH $72.39
- Analyst Decision
- FMC Buy
- GH Strong Buy
- Analyst Count
- FMC 12
- GH 22
- Target Price
- FMC $43.33
- GH $66.27
- AVG Volume (30 Days)
- FMC 2.4M
- GH 2.0M
- Earning Date
- FMC 10-29-2025
- GH 10-29-2025
- Dividend Yield
- FMC 7.62%
- GH N/A
- EPS Growth
- FMC N/A
- GH N/A
- EPS
- FMC 0.80
- GH N/A
- Revenue
- FMC $4,131,600,000.00
- GH $828,849,000.00
- Revenue This Year
- FMC N/A
- GH $28.28
- Revenue Next Year
- FMC $4.55
- GH $23.00
- P/E Ratio
- FMC $29.41
- GH N/A
- Revenue Growth
- FMC 1.16
- GH 28.74
- 52 Week Low
- FMC $28.80
- GH $20.14
- 52 Week High
- FMC $67.75
- GH $72.70
- Technical
- Relative Strength Index (RSI)
- FMC 42.80
- GH 68.36
- Support Level
- FMC $29.13
- GH $66.59
- Resistance Level
- FMC $30.24
- GH $70.33
- Average True Range (ATR)
- FMC 0.90
- GH 2.77
- MACD
- FMC 0.34
- GH 0.61
- Stochastic Oscillator
- FMC 79.71
- GH 95.03
About FMC FMC Corporation
FMC is a pure-play global crop protection company with a fairly balanced product portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop protection companies and focuses on the development of new products, including biologicals, through its research and development pipeline.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.